Kyle Wierzbicki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2058586/publications.pdf

Version: 2024-02-01

1478505 1588992 9 222 6 8 citations h-index g-index papers 12 12 12 330 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma. Neuro-Oncology, 2022, 24, 1366-1374.	1.2	36
2	Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR. Scientific Reports, 2021, 11, 5098.	3.3	31
3	EPCT-03. SERIAL PLASMA AND CSF CELL-FREE TUMOR DNA (CF-TDNA) TRACKING IN DIFFUSE MIDLINE GLIOMA PATIENTS UNDERGOING TREATMENT WITH ONC201. Neuro-Oncology, 2021, 23, i46-i47.	1.2	O
4	Electronic DNA Analysis of CSF Cell-free Tumor DNA to Quantify Multi-gene Molecular Response in Pediatric High-grade Glioma. Clinical Cancer Research, 2020, 26, 6266-6276.	7.0	26
5	Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma. Current Oncology Reports, 2020, 22, 19.	4.0	35
6	Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma. Journal of Clinical Investigation, 2020, 130, 5313-5325.	8.2	41
7	PDCT-12. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA. Neuro-Oncology, 2019, 21, vi186-vi186.	1.2	2
8	PDTM-29. CSF H3F3A K27M CIRCULATING TUMOR DNA COPY NUMBER QUANTIFIES TUMOR GROWTH AND TREATMENT RESPONSE. Neuro-Oncology, 2018, 20, vi209-vi210.	1.2	0
9	CSF H3F3A K27M circulating tumor DNA copy number quantifies tumor growth and in vitro treatment response. Acta Neuropathologica Communications, 2018, 6, 80.	5.2	50